COMMUNIQUÉS West-GlobeNewswire

YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy
29/01/2026
TAIWAN, Jan. 29, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations [...]
Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan
29/01/2026
Approximately 50% reduction in target lesion and greater than 90% decrease in CA-125 observed in endometrial cancer patient The unconfirmed partial response (uPR) that was observed in the first scan has been achieved at [...]
Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules
29/01/2026
DOYLESTOWN, Pa., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific [...]
SeaStar Medical to Present at Upcoming Noble Capital Markets Emerging Growth Virtual Equity Conference
29/01/2026
DENVER, Jan. 29, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and [...]
Applied Therapeutics Shares Letter to Stockholders Recommending Tender of Shares Following Offer Expiration Extension
29/01/2026
NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company” or “Applied”), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare [...]
Fedora Pharmaceuticals Highlights Efficacy of Novel Antibiotic, FPI-2119, against Antimicrobial-resistant Gram-negative Bacteria at the 2026 IMARI Conference
29/01/2026
FPI-2119 offers potential solution to multi-drug-resistant Gram-negative infections EDMONTON, Alberta , Jan. 29, 2026 (GLOBE NEWSWIRE) -- Fedora Pharmaceuticals, Inc., a leader in the development of drugs to treat [...]
Fortrea Announces Date for Fourth Quarter and Full Year 2025 Financial Results and Conference Call
29/01/2026
DURHAM, N.C., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its fourth quarter and full year 2025 [...]
Glucotrack Announces USPTO Approval for Issuance of Patents for Proprietary CBGM Platform
29/01/2026
RUTHERFORD, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc.(“Glucotrack”, or the “Company”) (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel [...]
Breakthru Medicine emerges from stealth with $60M Series A for cancer drug development
29/01/2026
PHOENIX, Ariz., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Breakthru Medicine emerges from stealth with the close of a $60M Series A financing round following a prior undisclosed seed round. Breakthru was founded by biotech [...]
Profusa Presents Positive US-Study Clinical Results at Leipzig Interventional Course (LINC) 2026
29/01/2026
Study conducted at US sites evaluates Lumee TM in peripheral artery disease (PAD) patients BERKELEY, Calif, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage [...]
Immutep Quarterly Activities Report Q2 FY26
29/01/2026
Media Release Entered into strategic collaboration with Dr. Reddy’s for commercialisation of eftilagimod alfa (efti) in all countries outside North America, Europe, Japan, and Greater China In January 2026, Immutep [...]
Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor
29/01/2026
REDWOOD CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first [...]
InnovAge Expands Board with Appointment of Two Directors
29/01/2026
DENVER, Jan. 29, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, and predominantly dual-eligible [...]
Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO)
29/01/2026
SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative [...]
Beghou’s Biopharma Commercialization Research Report Reveals Top Challenges, Opportunities, and Investment for Life Sciences Industry in 2026
29/01/2026
New research shows teams are struggling to execute coordinated actions across data, access, and omnichannel, leading to persistent gaps in performance AI is a top priority, but many technologies remain uneven in [...]
Apyx Medical Corporation to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
29/01/2026
CLEARWATER, Fla., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion ® and the AYON Body [...]
Soleno Therapeutics to Participate in Upcoming Conferences
29/01/2026
REDWOOD CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced [...]
InflaRx Announces Participation in February Investor Conferences
29/01/2026
JENA, Germany, Jan. 29, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate [...]
Glass House Brands Announces Appointment of Alison Payne, Heineken USA Chief Marketing Officer, to its Board of Directors
29/01/2026
Ms. Payne brings decades of international marketing experience from Heineken, PepsiCo, Kellog and Diageo, where she specializes in branding regulated consumer products LONG BEACH, Calif. and TORONTO, Jan. 29, 2026 ( [...]

Pages